2'-Deoxy-2'-fluorouridine-d₂ 

2'-Deoxy-2'-fluorouridine-d₂ is the deuterium labeled 2'-Deoxy-2'-fluorouridine^[1]. 2'-Deoxy-2'-fluorouridine is a derivative of the pyrimidine nucleoside uridine. 2'-Deoxy-2'-fluorouridine is a nucleoside analog that inhibits the replication of wild-type viruses by binding to the viral RNA. Hepatitis C polyU/UC RNA strands containing 2'-Deoxy-2'-fluorouridine, bind to RIG-I but do not activate RIG-I signaling in a reporter assay using Huh7 cells. 2'-Deoxy-2'-fluorouridine also has been used as a starting material in the synthesis of respiratory syncytial virus (RSV) polymerase inhibitors. 2'-Deoxy-2'-fluorouridine can incorporate into DNA and RNA in rat and woodchuck model upon administration. 2'-Deoxy-2'-fluorouridine can be studied in anti-viral research^[1][2][3][4].

氢、碳和其他元素的稳定重同位素已被掺入药物分子中，主要用作药物研发过程中定量分析的示踪剂。氘化因其可能影响药物的药代动力学和代谢特征而备受关注^[5]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

248.20

C₉H₉D₂FN₂O₅

362049-50-1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. J V Tuttle, et al. Purine 2'-deoxy-2'-fluororibosides as antiinfluenza virus agents. J Med Chem  [Content Brief]

  [2]. Durbin, A. F., et al., (2016). RNAs Containing Modified Nucleotides Fail To Trigger RIG-I Conformational Changes for Innate Immune Signaling. mBio, 7(5), e00833-16.  [Content Brief]

  [3]. Wang, G., et al., (2015). Discovery of 4'-chloromethyl-2'-deoxy-3',5'-di-O-isobutyryl-2'-fluorocytidine (ALS-8176), a first-in-class RSV polymerase inhibitor for treatment of human respiratory syncytial virus infection. Journal of medicinal chemistry, 58(4), 1862–1878.  [Content Brief]

  [4]. Richardson, F. C., et al., (2002). Quantification of 2'-fluoro-2'-deoxyuridine and 2'-fluoro-2'-deoxycytidine in DNA and RNA isolated from rats and woodchucks using LC/MS/MS. Chemical research in toxicology, 15(7), 922–926.  [Content Brief]

  [5]. Russak, E. M., & Bednarczyk, E. M. (2019). Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. The Annals of pharmacotherapy, 53(2), 211–216.  [Content Brief]